Aspira women's health announces the publication of three abstracts by the american society of clinical oncology (asco) supporting the clinical utility of ovasuite(sm) ovarian cancer risk assessment tests

Austin, texas, may 31, 2023 (globe newswire) -- aspira women's health inc. (“aspira”) (nasdaq: awh), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, announced the online publication of three abstracts supporting the clinical utility of ovawatchsm at the 2023 american society of clinical oncology (asco) meeting taking place in chicago, il on june 2-6, 2023. these abstracts were co-authored by the aspira women's health innovation team and dr. gerard reilly, director of clinical research and innovation at axia women's health.
AWH Ratings Summary
AWH Quant Ranking